Citigroup Maintains Neutral on Teladoc Health, Raises Price Target to $7

Benzinga Newsdesk www.benzinga.com Neutral 54.5%

Neg 0% Neu 54.5% Pos 0%

Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:TDOC) with a Neutral and raises the price target from $6 to $7.